Drug-eluting stent coatings

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 1, Issue 4, 2009, Pages 451-462

  Puskas, Judit E ^a   Muñoz Robledo, Lyn G ^a   Hoerr, Robert A ^b   Foley, John ^b   Schmidt, Steven P ^c   Evancho Chapman, Michelle ^c   Dong, Jinping ^d   Frethem, Chris ^d   Haugstad, Greg ^d  

^a UNIVERSITY OF AKRON   (United States)

^b Nanocopoeia Inc   (United States)

^c SUMMA HEALTH SYSTEM   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOSTON SCIENTIFIC; CLINICAL PRACTICES; DRUG-ELUTING STENTS; ELECTRONANOSPRAY; INTERDISCIPLINARY TEAMS; NANO-SIZED PARTICULATES; POLY(STYRENE-B-ISOBUTYLENE-B-STYRENE) SIBS; POLYMERIC COATINGS;

BIOCOMPATIBILITY; DRUG PRODUCTS; PLASTIC COATINGS; POLYMER BLENDS; POLYMERS; STYRENE;

STENTS;

BIOMATERIAL; POLYMER;

CHEMISTRY; DRUG ELUTING STENT; HUMAN; METHODOLOGY; NANOTECHNOLOGY; REVIEW;

BIOCOMPATIBLE MATERIALS; DRUG-ELUTING STENTS; HUMANS; NANOTECHNOLOGY; POLYMERS;

EID: 74049119439     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.38     Document Type: Review

References (65)

1. Moses JW, Weisz G, Mishkel G, Caputo R, O'shaughnessey C, et al. Catheterization and cardiovascular interventions. Catheter Cardiovasc Interv 2007, 70(4):505-512.
2. Fontos G. Drug eluting coronary stents. Orv Hetil 2006, 147(43):2059-2066.
3. Sutton AGC, Campbell PG, Graham R, Price DJA, Gray JC, et al. One year results of the Middlesborough early revascularization to limit infarction (MERLIN) trial. Heart (British Cardiac Society) 2005, 91(10):1330-1337.
4. Arjomand H, Turi Z, McCormick D, Goldberg S. Percutaneous coronary intervention: historical perspectives, current status, and future direction. Am Heart J 2003, 146:787-796.
5. Jenkins NP, Predergast BD, Thomas M. Drug eluting coronary stents. BMJ 2002, 325:1315-1316.
6. Bitl JA, Scwartz L, Serruys PW, Fischmann DL, Savage SP, et al. Coronary-Stent placement compared with balloon angioplasty. N Engl J Med 1995, 332: 536-538.
7. Serruys PW, Jaegere PD, Kiemenij F, Macaya C, Rutsch W, et al. A comparison of balloon-expandablestent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994, 331:489-495.
8. Grüntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet 1978, 1(8058):263.
9. Palmaz JC, Richter GM, Noldge G, Kauffmann GW, Wenz WDR. Intraluminal Palmaz stent implantation. First clinical case report on a balloonexpanded vascular prosthesis. Radiologe 1987, 27(12): 560-563.
10. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty.NEngl J Med 1987, 316:701-706.
11. Erbel R, Schatz R, Dietz U, Nixdorff U, Haude M, et al. Balloon dilatation and coronary vascular stent implantation. Z Kardiol 1989, 78(2):71-77.
12. Miller LA, Briscoe A, Bailey SR,WrightWT Jr, Ebersole DG. Care of the elective intracoronary stent patient. Crit Care Nurs Q 1996, 18(4):777-791.
13. Gerschlick AH, Baron J. Dealing with in-stent restenosis. Heart 1998, 79:319.
14. Morice MA, Serruys PW, Sousa JE, Fajadet J, Hayashi EB, et al. A randomized comparison of a sirolimuseluting stent with a standard stent for coronary revascularization. N Engl JMed 2002, 346:1773-1780.
15. Bhatia V, Bhatia R, Dhinkda SJ. Drug-eluting intracoronary stents: Have we got the magic bullet. J PostgradMed 2003, 49:291-296.
16. Stone GW, Ellis SG, O'Shaughnessy CD, et al. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents the TAXUS V ISR randomized trial. JAMA 2006, 295:1253-1263.
17. Ratner BD. New ideas in biomaterials science, A path to engineered biomaterials. J Biomed Mater Res 1993, 27(7):837-850.
18. Pinchuk L, Wilson GJ, Barry JJ, Schoephoerster RT, Parel JM, et al. Medical applications of poly(styrene-block-isobutylene-block-styrene) (''SIBS''). Biomaterials 2008, 29:448-460.
19. Ven der Giessen W, Lincoff AM, Schwartz RS, van Beusekom HMM, Serruyset PW, et al. Marked inflammatory sequalae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996, 94:1690-1697.
20. Pinchuk L. A review of the biostability and carcinogenicity of polyurethanes in medicine and the new generation of 'biostable' polyurethanes. J Biomater Sci Polym Ed 1994, 6(3):225-267.
21. Wache HM, Tartakowska DJ, Hentrich A. Wagner: Development of a polymer stent with shape memory effect as a drug delivery system. J Mater Sci Mater Med 2003, 14:109-112.
22. Muni NI, Gross TP. Problems with drug-eluting coronary stents- The FDA perspective. N Engl J Med 2004, 351:1593-1595.
23. Weber F, Schneider H, Schwarz C, Holzhausen C, Petzsch M, et al. Sirolimus- eluting stents for percutaneous coronary intervention in acute myocardial infarction. Z Kardiol 2004, 93:938-943.
24. Morice MC, Serruys PW, Barragan P, Bode C, Van Es GA, et al. Long-term clinical outcomes with sirolimuseluting coronary stents: five-year results of the RAVEL trial. J Am Coll Cardiol 2007, 50(14):1299-1304.
25. Morice MA, Serruys PW, Sousa JE, Fajadet J, Hayashi EB, Perin M, et al. A randomized comparison of a sirolimus eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002, 346:1773-1780.
26. Kennedy JP, Kaszas G, Puskas JE, Hager WG. Thermoplastic elastomers of isobutylene and process of preparation. U.S. Patent 4,946,899, August 7, 1990.
27. Lawrence SS, Shinozaki DM, Puskas JE, Gerchcovich M, Myler U. Micro-mechanical testing of polyisobutylene-polystyrene block-type thermoplastic elastomers. Rubber Chem. Technol. 2001, 74:601-613.
28. Puskas JP, Paulo C, Antony P. Arborescent thermoplastic elastomers and products therefrom. U.S. Patent 6,747,098, June 8, 2004.
29. Cadieux P, Watterson JD, Harbottle R, Howard J, Puskas JE, et al. A new biomaterial for application to the urinary tract, and potential for lactobacillus proteins to reduce the risk of device-associated infections. J Colloids Surf B Biointerfaces 2002, 28(2-3): 95-105.
30. Puskas JE, Chen Y, Antony P, Kwon Y, Kovar M, et al. Atomic force microscopic and encrustation studies of novel prospective polyisobutylene-based thermoplastic elastomeric biomaterials. Polym Adv Technol 2003, 14(11-12):763-770.
31. Antony P, Kwon Y, Puskas JE, Kovar M, Norton PR. Atomic force microscopic studies of polystyrenepolyisobutylene block copolymers. Eur Polym J 2003, 40:149-157.
32. Puskas JE, Antony P, El Fray M, Altstädt V. Effect of hard and soft segment composition on the mechanical properties of polyisobutylene-polystyrene thermoplastic elastomeric block copolymers. Eur Polym J 2003, 39:2041-2049.
33. Puskas JE, Chen Y. Biomedical application of commercial polymers and novel polyisobutylene-based thermoplastic elastomers for soft tissue replacement. Biomacromolecules 2004, 5(4):1141-1154 (German) GAK-GV. 2004 7:455-461; 8:526-534.
34. Puskas JE, Chen Y, Dahman Y, Padavan D. Polyisobutylene-based biomaterials. Feature article. J Polym Sci Chem 2004, 42(13):3091-3109.
35. Kennedy JP, Puskas JE, Holden G, Kricheldorf HR, Quirk RP. Thermoplastic Elastomers. 3rd ed. Munich: Hanser Publishers; 2004.
36. Puskas JE, Kwon Y, Prince A, Bhowmick AK. Synthesis and characterization of novel dendritic(arborescent, hyperbranched) polyisobutylene-polystyrene. J Polym Sci [A1] 2005, 43:1811-1826.
37. Puskas JE, Dos Santos L, Kaszas G. Innovation in material science: the chameleon block copolymer. J Polym Sci Chem 2006, 44:6494-6497.
38. El Fray M, Prowans P, Puskas JE, Altstädt V. Biocompatibility and fatigue properties of polystyrenepolyisobutylene- polystyrene, an emerging thermoplastic elastomeric biomaterial. Biomacromolecules 2006, 7(3):844-850.
39. Puskas JE, Kwon Y. Biomacromolecular engineering: desing, synthesis and characterization one-post synthesis of block copolymers of arborescent polyisobutylene and polystyrene. Polym Adv Technol 2006, 17:615-620.
40. Foreman EA, Puskas JE, Kaszas G. Synthesis and characterization of arborescent (hyperbranched) polyisobutylenes from the 4-(1,2-oxirane-isopropyl)styrene inimer. J Polym Sci Chem 2007, 45:5847-5856.
41. Turco MA, Ormiston JA, Popma JJ, Mandinov L, O'Shaughnessy CD, et al. Polymer-based, paclitaxeleluting TAXUS Liberte stent in de novo lesions: the pivotal TAXUS ATLAS trial. J Am Coll Cardiol 2007, 49(16):1676-1683.
42. Keiichi T, Serruys PW, Bruining N, Dudek D, Drzewiecki J, et al. Two-year serial coronary angiographic and intravascular ultrasound analysis of in-stent angiographic late lumen loss and ultrasonic neointimal volume from the TAXUS II trial. Am J Cardiol 2007, 99(5):607-615.
43. Moses JW, Mehran R, Nikolsky E, Lasala JM, Corey W, et al. Outcomes with the paclitaxel-eluting stent in patients with acute coronary syndromes: analysis from the TAXUS-IV trial. J Am Coll Cardiol 2005, 45(8):1165-1171.
44. Ranade SV, Richard RE, Helmus MN. Styrenic block copolymers for biomaterial and drug delivery applications. Acta Biomater 2005, 1:137-144.
45. Ranade SV, Miller KM, Richard RE, Chan AK, Allen MJ, Helmus MN. et al. Physical characterization of controlled release of paclitaxel from the TAXUSTM Express2TM drug eluting stent. J Biomed Mater Res 2004, 71A(4):625-634.
46. Long D. DES2.0-and beyond. AHC Media LLC Cardiovascular Device Update?. AHC Media 2007, 13(2):1-7.
47. Lagerqvist B, James SK, Stenestrand U, Lindbäck J, Nilsson T, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007, 356:1009-1019.
48. Galoe AM, Thuesen L, Kelbaek H, Thayssen P, Rasmussen K, et al. Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial. JAMA 2008, 299(4):409-416.
49. Blagosklonny MV, Darzynkiewicz Z, Halicka HD, Pozarowski P, Demidenko ZN. Paclitaxel induces primary and postmitotic g1 arrest in human arterial smooth muscle cells. Cell Cycle 2004, 3(8):1050-1056.
50. Haude M, Erbel R, Straub U, Dietz U, Schatz R, et al. Results of intracoronary stents formanagement of coronary dissection after balloon angioplasty. Am J Cardiol 1991, 67(8):691-696.
51. Schatz RA, Baim DS, Leon M, Ellis SG, Goldberg S, et al. Clinical experience with the Palmaz-Schatz coronary stent. Initial results of a multicenter study. Circulation 1991, 83(1):148-161.
52. Cutlip DE, Baim DS, Ho KK, Popma JJ, Lansky AJ, et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 2001, 103(15):1967-1971.
53. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl JMed 2003, 349(14):1315-1323.
54. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, et al. A polymer-based paclitaxeleluting stent in patients with coronary artery disease. N Engl JMed 2004, 350(3):221-231.
55. Kereiakes DJ. The Emperor's new clothes: another cipher versus taxus post-hoc meta-analysis. J Am Coll Cardiol 2007, 50(14):5.
56. Bavry AA, Kumbhani DJ, Helton TJ, Bhatt DL. What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention? A meta-analysis. J Am Coll Cardiol 2005, 45(6):941-946.
57. Pfisterer ME, Kaiser CA, Bader F, Brunner-La Rocca HP, Bonetti PO. BASKET-LATE: Late clinical events related to late stent thrombosis after stopping clopidogrel: Drug-eluting vs bare-metal stenting. In American College of Cardiology 55th Annual Scientific Meeting, Atlanta, GA, 2006, Abstract 422-11.
58. Camenzind E, Steg PG, Wijns W. A cause for concern. Circulation 2007, 115:1440-1455.
59. Leon BM. Independent physician-led patient-level analysis: TAXUS randomized trials. In Program and abstracts from the Transcatheter Cardiovascular Therapeutics 18th Annual Scientific Symposium, Washington, DC, October 22-27, 2006.
60. Stone GW. Independent physician-led patient-level analysis: CYPHER randomized trials. In Program and abstracts from the Transcatheter Cardiovascular Therapeutics 18th Annual Scientific Symposium, Washington, DC, October 22-27, 2006.
61. Bavry AA, Bhatt DL. Appropriate use of drugeluting stents: balancing the reduction restenosis with the concern of late thrombosis. Lancet 2008, 371(9630):2134-2143.
62. MarroquinOC, Mulukutla SR, Kip KE. Bare-metal versus drug-eluting coronary stents. N Engl J Med 2008, 358(23):2517-2518.
63. Pierfrancesco A, Vermersch P. Bare-metal versus drugeluting coronary stents New England. J Med 2008, 358(23):2516-2517.
64. Austin D, Pell JP, Oldroyd KG. Bare-metal versus drug-eluting coronary stents. N Engl J Med 2008, 358(23):2516.
65. Pui DYH, Chen DR. Electrospraying Apparatus and Method for Coating Particles. US Patent 6,746,869, June 8, 2004.